Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

Positive results from the global PREVAIL phase III trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.

Oral therapy showed dose-dependent increases in progranulin protein levels in both plasma and cerebrospinal fluid; >95% mean increase in progranulin levels in CSF, compared to baseline; favorable ...

The FTSE 100 Index has been in a strong bull run this year and is now trading at a record high of £9,760. It has jumped by 30% from its lowest point this year. The index jumped this week as the ...

Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356 Technology appraisal guidance TBC Obecabtagene autoleucel for treating relapsed or ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living. Read More ...

Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and ...